Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe results from clinical trials of novel agents for the treatment of patients with prostate cancer
- Discuss the use of tyrosine kinase inhibitors, alone and in combinations, for the treatment of prostate and bladder cancers
- Cite cardiovascular complications associated with targeted agents
Topics covered include:
- Introduction
- Treatment of Prostate Cancer With Abiraterone, a Novel Androgen Synthesis Inhibitor
- Endothelin-A Receptor Antagonists in Prostate Cancer
- Novel Tyrosine Kinase Inhibitors in Prostate Cancer
- Prostate Cancer Data Summary
- Bevacizumab Plus Interferon in Renal Cell Cancer
- Bevacizumab Plus Sunitinib in Renal Cell Cancer
- Cardiovascular Complications With Targeted Agents
- Gemcitabine and Radiotherapy in Bladder Cancer
- Tyrosine Kinase Inhibitors in Bladder Cancer
- Other Topics in Bladder Cancer
- Testicular Cancer
- Translational Studies
- Concluding Remarks